Site is Being Upgraded

Unknown action of a known drug in body weight control, energy homeostasis and TIIDM:Bromocriptine (trade name:Parlodel), used in the treatment of  pituitary tumors, Parkinson’s disease (PD), hyperprolactinaemia, infertility and others, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 1/June/2018, 11.14 pm

Combinatorial therapy for cardiomyocyte proliferation and heart regeneration: A pharmaceutical mixture encompassing L-Malate, Lithium and Imidazopyridine derivative (X22) (MLX22) decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up regulation of its target gene, 1/June/2018, 10.51 pm
June 1, 2018
Locking blood sugar disease with an interleukin therapy: Interleukin(IL-2)-based therapy for TIIDM: IL-2 increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 1/June/2018, 11.23 pm
June 1, 2018
Show all

Introduction: What they say

A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.” This research paper was published, in the 29 March 2012 issue of the journal “Nature” [One of the best research journals in Science with an I.F of 43 plus], by Prof.Burris TP, Solt LA and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Unknown action of a known drug in body weight control, energy homeostasis and TIIDM:Bromocriptine (trade name:Parlodel), used in the treatment of  pituitary tumors, Parkinson’s disease (PD), hyperprolactinaemia, infertility and others, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) more than half a billion adults are obese worldwide ; (2) obesity is more prevalent in western countries than in asian countries; (3) obesity results in deregulated blood pressure, cholesterol, triglycerides and insulin sensitivity; and the risks of coronary heart disease, ischemic stroke and TII diabetes mellitus(TIIDM) increase ; (4) more than 422 million people worldwide are affected by Diabetes mellitus (DM); (5) Diabetes is going to be one of the top 10 causes of death by 2030; (6) the life-long painful injection/drug treatment is required to treat DM; and  (7) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, obesity-associated diseases, including diabetes.


What is known?

Prof.Burris’s research team has recently shown that administration of REV-ERB ligands:(1) regulates circadian behaviour and the circadian pattern of core clock gene;(2) alters the circadian pattern of expression of metabolic genes in liver, skeletal muscle and adipose tissue; (3) increases energy expenditure; (4) inhibits lipid accumulation; (4) decreases obesity; (5) improves dyslipidemia; and (6) reduces hyperglycaemia, suggesting that increasing the expression of REV-ERB may promote weight loss, augment insulin sensitivity, improve dyslipidemia and alleviate Obesity-associated TIIDM.


From Research findings to Therapeutic opportunity:

This study reveals, for the first time, an unknown action of a known drug–Bromocriptine–in body weight control, energy homeostasis and TIIDM. Bromocriptine, by increasing the expression of its target gene, it may increase the expression of REV-ERB. Thereby, it may: (1) normalize circadian pattern of metabolic genes; (2) augment energy expenditure; (3) inhibit lipid accumulation; (4) promote weight loss; (5) ameliorate dyslipidemia; and (6) inhibit hyperglycemia (Fig.1). Thus, pharmacological formulations encompassing Bromocriptine or its analogues , either alone or in combination with other drugs” may be used:(i) as a weight-loss medication; (ii) to treat Obesity-associated TIIDM; (iii) to treat sleep disorders (Fig.2).

Figure 1. Mechanistic insights into how Bromocriptine attenuates metabolic disease and obesity-associated TIIDM.  Bromocriptine, by up regulating the expression of REV-ERB, it may attenuate metabolic disease.

Figure 2. Bromocriptine promotes weight loss and attenuates metabolic disease.

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Bromocriptine increase the expression of REV-ERB?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

 

Citation: Boominathan, L.,  Unknown action of a known drug in body weight control, energy homeostasis and TIIDM:Bromocriptine (trade name:Parlodel), used in the treatment of  pituitary tumors, Parkinson’s disease (PD), hyperprolactinaemia, infertility and others, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 1/June/2018, 11.14 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

 

 

 

Comments are closed.